Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia
Journal
Leukemia Research
Journal Volume
81
Pages
95-97
Date Issued
2019
Author(s)
SDGs
Other Subjects
dasatinib; entecavir; hepatitis B antibody; hepatitis B core antibody; hepatitis B surface antigen; hepatitis B(e) antigen; imatinib; nilotinib; ponatinib; protein tyrosine kinase inhibitor; virus DNA; protein kinase inhibitor; adult; aged; antiviral therapy; chronic myeloid leukemia; cohort analysis; female; follow up; hepatitis B; Hepatitis B virus; human; incidence; Letter; major clinical study; male; middle aged; priority journal; retrospective study; serology; treatment outcome; virus carrier; virus reactivation; young adult; adolescent; chronic myeloid leukemia; drug effect; hepatitis B; pathology; prognosis; Taiwan; very elderly; virology; virus activation; Adolescent; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Virus Activation; Young Adult
Publisher
Elsevier Ltd
Type
letter